Alternatively, PLCG2 mutations may predispose patients to autoimmunity-driven lung injury, akin to proposed autoimmune mechanisms in COPD, wherein immune cells target alveolar structures, triggering progressive destruction [[10], [11]]. The gene discussed is PLCG2; the disease is chronic obstructive pulmonary disease.